John Martinez - IShares Global Independent Trustee
| IXJ Etf | USD 93.95 0.39 0.42% |
Mr. John E. Martinez is an Independent Trustee of iShares Global Healthcare ETF. Mr. Martinez has served as a Director of iShares, Inc. since 2003 and a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010. Mr. Martinez is a Director of FirstREX Agreement Corporationration, providing governance oversight and consulting services to this privately held firm that develops products and strategies for homeowners in managing the equity in their homes. Mr. Martinez previously served as Director of Barclays Global Investors UK Holdings, where he provided governance oversight representing BGIs shareholders through oversight of BGIs worldwide activities. Since 2003, he is a Director and Executive Committee Member for Larkin Street Youth Services, providing governance oversight and strategy development to an agency that provides emergency and transitional housing, health care, education, job and life skills training to homeless youth
| Age | 55 |
| Tenure | 21 years |
| Professional Marks | MBA |
| Web | http://www.ishares.com/us/products/239744/ishares-global-healthcare-etf |
| Issuer | iShares |
| Inception Date | 2001-11-13 |
| Benchmark | S&P Global 1200 Healthcare Sector Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 4.04 Billion |
| Average Trading Valume | 121,075.1 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Blended Development |
IShares Global Management Efficiency
The company has Return on Asset of 0.88 % which means that on every $100 spent on assets, it made $0.88 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 23.19 %, implying that it generated $23.19 on every 100 dollars invested. IShares Global's management efficiency ratios could be used to measure how well IShares Global manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| Scott Zoltowski | SPDR SP Biotech | 43 | |
| Mary Zeven | SPDR SP Biotech | 51 | |
| Charles Hurty | iShares Medical Devices | 72 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Chad Hallett | SPDR SP Biotech | 46 | |
| Robert Silver | iShares Healthcare ETF | 57 | |
| Kathryn Hyatt | Vanguard Health Care | 57 | |
| Madhav Rajan | iShares Medical Devices | 52 | |
| Matthew Flaherty | SPDR SP Biotech | 41 | |
| Heidi Stam | Vanguard Health Care | 56 | |
| Amy Gutmann | Vanguard Health Care | 63 | |
| Emerson Fullwood | Vanguard Health Care | 70 | |
| Peter Ambrosini | SPDR SP Biotech | 68 | |
| Gary French | SPDR SP Biotech | 67 | |
| Alfred Rankin | Vanguard Health Care | 76 | |
| John Tucker | Health Care Select | N/A | |
| JoAnn Heisen | Vanguard Health Care | 62 | |
| Madhav Rajan | iShares Healthcare ETF | 52 | |
| John Kerrigan | iShares Medical Devices | 60 | |
| Rajiv Gupta | Vanguard Health Care | 72 | |
| John Clark | SPDR SP Biotech | 45 | |
Management Performance
| Return On Equity | 23.19 | |||
| Return On Asset | 0.88 |
iShares Global Healthcare Money Managers
| Robert Silver, Independent Chairman of the Board of the Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Edward Baer, Vice President Chief Legal Officer | ||
| Eilleen Clavere, Secretary | ||
| Scott Radell, Executive Vice President | ||
| George Parker, Independent Trustee | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Global a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 23.19 | |||
| Return On Asset | 0.88 | |||
| Operating Margin | 76.50 % | |||
| Current Valuation | 3.06 B | |||
| Shares Outstanding | 35.85 M | |||
| Shares Owned By Institutions | 72.32 % | |||
| Price To Earning | 5.54 X | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.93 X | |||
| Revenue | 43.28 M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as iShares Global Healthcare using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in IShares Etf
When determining whether iShares Global Healthcare is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if IShares Etf is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ishares Global Healthcare Etf. Highlighted below are key reports to facilitate an investment decision about Ishares Global Healthcare Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Global Healthcare. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
The market value of iShares Global Healthcare is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Global's value that differs from its market value or its book value, called intrinsic value, which is IShares Global's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Global's market value can be influenced by many factors that don't directly affect IShares Global's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Global's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Global is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Global's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.